J Alfred Witjes Selected Research

Mitomycin (Mitomycin-C)

1/2019	Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
11/2018	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue.
7/2018	Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model.
5/2018	[Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]
1/2017	Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
1/2016	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
9/2014	Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
6/2012	Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
10/2009	Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
8/2009	An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Alfred Witjes Research Topics

Disease

70	Urinary Bladder Neoplasms (Bladder Cancer) 05/2022 - 09/2003
58	Neoplasms (Cancer) 01/2022 - 07/2003
50	Non-Muscle Invasive Bladder Neoplasms 08/2022 - 01/2008
50	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 07/2003
22	Carcinoma (Carcinomatosis) 03/2022 - 08/2004
10	Carcinoma in Situ 01/2019 - 07/2005
9	Hyperthermia 01/2021 - 09/2003
8	Neoplasm Metastasis (Metastasis) 10/2021 - 08/2004
6	Margins of Excision 01/2020 - 03/2010
4	Testicular Neoplasms (Testicular Cancer) 01/2021 - 06/2003
4	Obesity 12/2010 - 01/2009
3	Pain (Aches) 01/2022 - 11/2007
3	Residual Neoplasm 01/2022 - 04/2010
2	Disease Progression 09/2020 - 01/2018
2	Body Weight (Weight, Body) 07/2018 - 11/2004
2	Lymphatic Metastasis 03/2012 - 05/2009
1	Postoperative Hemorrhage 01/2022
1	Nonseminomatous germ cell tumor 01/2021
1	Pelvic Neoplasms 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020
1	Hypersensitivity (Allergy) 11/2019
1	Inflammation (Inflammations) 02/2017
1	Extranodal Extension 01/2016
1	Neutropenia 01/2015
1	Thrombocytopenia (Thrombopenia) 01/2015

Drug/Important Bio-Agent (IBA)

14	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2019 - 09/2003
11	5-aminolevulinic acid hexyl ester FDA Link 04/2016 - 03/2005
9	Biomarkers (Surrogate Marker)IBA 08/2022 - 07/2004
9	Messenger RNA (mRNA)IBA 01/2021 - 08/2004
9	Prostate-Specific Antigen (Semenogelase)IBA 07/2015 - 07/2004
6	Gemcitabine FDA Link 01/2022 - 09/2003
6	apaziquone (E 09)IBA 07/2018 - 04/2005
5	AntigensIBA 01/2022 - 02/2007
5	Hormones (Hormone)IBA 01/2022 - 09/2020
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2015
5	Epirubicin (Ellence)FDA LinkGeneric 02/2016 - 04/2005
5	Contrast MediaIBA 01/2013 - 11/2005
4	PlatinumIBA 01/2021 - 11/2009
4	Proteins (Proteins, Gene)FDA Link 05/2017 - 07/2006
4	Pharmaceutical PreparationsIBA 02/2014 - 04/2006
4	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 12/2013 - 11/2004
4	Protons (Proton)IBA 11/2008 - 11/2006
3	Toll-Like Receptor 7IBA 11/2018 - 06/2013
3	AcidsIBA 10/2013 - 10/2007
3	DNA (Deoxyribonucleic Acid)IBA 05/2010 - 07/2006
3	SurvivinIBA 07/2006 - 08/2004
2	LutetiumIBA 11/2021 - 09/2020
2	AndrogensIBA 11/2021 - 07/2013
2	Liposomes (Liposome)IBA 01/2021 - 01/2021
2	Long Noncoding RNAIBA 07/2018 - 05/2017
2	Biological ProductsIBA 01/2018 - 08/2008
2	Imiquimod (Aldara)FDA LinkGeneric 06/2015 - 06/2013
2	GoldIBA 12/2011 - 11/2007
2	RNA (Ribonucleic Acid)IBA 09/2007 - 07/2003
2	N-acetyltalosaminuronic acid (NAT)IBA 10/2006 - 08/2005
1	177Lu-PSMA-617IBA 11/2021
1	Genetic Markers (Genetic Marker)IBA 11/2021
1	pembrolizumabIBA 08/2021
1	NivolumabIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	PhosphatidylglycerolsIBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	PSMA I&TIBA 09/2020
1	Protamines (Protamine Sulfate)FDA Link 11/2019
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 09/2019
1	Fluorouracil (Carac)FDA LinkGeneric 01/2019
1	Immunologic Factors (Immunomodulators)IBA 11/2018
1	TMX-202IBA 11/2018
1	HydrogelsIBA 07/2018
1	Interleukin-2 (IL2)IBA 01/2018
1	SeleniumIBA 02/2017
1	BCG ConnaughtIBA 11/2016
1	Interleukin-18 (Interleukin 18)IBA 01/2016

Therapy/Procedure

46	Therapeutics 01/2022 - 09/2003
32	Drug Therapy (Chemotherapy) 01/2021 - 12/2004
29	Cystectomy 03/2022 - 09/2003
22	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 11/2005
11	Intravesical Administration 11/2018 - 09/2006
10	Radiotherapy 01/2021 - 09/2003
10	Immunotherapy 11/2019 - 09/2006
8	Transurethral Resection of Bladder 01/2022 - 06/2009
8	Lymph Node Excision (Lymph Node Dissection) 12/2020 - 05/2008
5	Castration 01/2022 - 11/2019
5	Aftercare (After-Treatment) 01/2021 - 06/2003
3	Neoadjuvant Therapy 01/2022 - 12/2020
2	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 01/2015
2	Brachytherapy 06/2011 - 01/2010
1	Urinary Diversion (Ileal Conduit) 05/2022
1	Operative Time 01/2022
1	Adrenalectomy 01/2022
1	Robotic Surgical Procedures 01/2022
1	Induced Hyperthermia (Thermotherapy) 01/2021
1	Maintenance Chemotherapy 01/2021
1	Length of Stay 01/2020
1	Treatment Delay 11/2019
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Laser Therapy (Surgery, Laser) 05/2017
1	Chemoprevention 02/2017
1	Patient Care 03/2016